427 material Form 8-K filings that 376 companies we cover made with the SEC in September 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Arrowhead Pharmaceuticals entered an exclusive license and collaboration agreement with Novartis for ARO-SNCA, a preclinical RNA interference therapy for Parkinson's Disease and other synucleinopathies, plus additional collaboration targets. Arrowhead will receive a $200 million upfront payment upon closing and is eligible for up to $2 billion in milestones and tiered royalties up to the low double digits on net sales, but the deal remains subject to closing conditions including the Hart-Scott-Rodino waiting period.
Upfront payment of $200 million to Arrowhead, payable upon closing
Eligible for up to $2 billion in development, regulatory and sales milestones, plus royalties up to the low double digits
Novartis takes sole control of clinical development, manufacturing and commercialization after Arrowhead completes preclinical work
Transaction expected to close in the second half of 2025, subject to Hart-Scott-Rodino and other customary conditions
HealthEquity reported results for the quarter ended July 31, 2025, with revenue of $325.8 million, up 9% from a year earlier, and GAAP net income of $59.9 million, or $0.68 per diluted share, up from $0.40. The company also set fiscal 2026 outlook calling for revenue of $1.290 billion to $1.310 billion and GAAP net income per diluted share of $2.11 to $2.28.
Q2 revenue was $325.8 million, up 9% from $299.9 million; adjusted EBITDA was $151.1 million, up 18%.
GAAP net income was $59.9 million, or $0.68 per diluted share, versus $35.8 million, or $0.40, a year earlier.
For the fiscal year ending January 31, 2026, the company expects revenue of $1.290 billion to $1.310 billion and adjusted EBITDA of $540 million to $560 million.
The company repurchased 0.7 million shares for $66.0 million in the quarter, with $351.8 million remaining authorized as of July 31, 2025.
Phillips Edison & Company's board approved a 5.7% increase in its monthly distribution to $0.1083 per share, or $1.30 annualized, up from $1.23. The company also disclosed a third amendment to its credit agreement with PNC Bank, which removes the credit spread adjustment on SOFR and adds sustainability-linked KPIs that may adjust the interest rate margin. For shareholders, the filing shows a higher distribution rate and a change to the cost terms of the company's credit facility.
Monthly distribution of $0.1083 per share, or $1.30 annualized, up 5.7% from $1.23 annualized
Distributions payable October 1, 2025 (September record date, September 15) and November 4, 2025 (October record date, October 15)
Third amendment dated August 29, 2025 removes the SOFR credit spread adjustment and adds sustainability KPIs that may adjust the interest rate margin
CEO Jeff Edison cited the fifth consecutive annual distribution increase and the second consecutive increase above 5%
Solventum completed the sale of its Purification & Filtration business to Thermo Fisher Scientific on September 1, 2025, for approximately $4.0 billion in cash before adjustments. The company said net proceeds of $3.4 billion will be used primarily to pay down debt, and it raised its adjusted EPS guidance for 2025, which shareholders may view as a positive development.
Sale closed September 1, 2025; cash consideration was approximately $4.0 billion, subject to closing adjustments, and Solventum may pay Buyer up to $75 million
Net proceeds of $3.4 billion will be used primarily to pay down outstanding debt
Adjusted EPS guidance raised to $5.88 to $6.03 from $5.80 to $5.95
Expected net interest expense lowered to $400 million from $450 million; organic sales growth (+2.0% to +3.0%) and free cash flow ($450 million to $550 million) guidance unchanged
Signet Jewelers reported second quarter fiscal 2026 sales of $1.5 billion, up 3.0% from a year earlier, with same store sales up 2.0%. Adjusted diluted EPS rose to $1.61 from $1.25, and the company raised its full-year fiscal 2026 adjusted diluted EPS guidance to $8.04 to $9.57. GAAP results were a loss of $0.22 per diluted share, which includes $2.01 per share of impairment and restructuring charges.
Q2 sales of $1,535.1 million, up $44.1 million or 3.0%; same store sales up 2.0%
GAAP diluted loss of $0.22 per share, compared with a loss of $2.28 in the year-earlier quarter
Fiscal 2026 adjusted diluted EPS guidance raised to $8.04 to $9.57 from $7.70 to $9.38
Third quarter adjusted operating income guidance of $3 million to $17 million; quarterly dividend of $0.32 per share payable November 21, 2025
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.